[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338592-105":59,"doc-detail-338592-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","lynch-syndrome-diagnostic-testing-pathways-in-endometrial-cancers-a-nationwide-english-registry-based-study","Lynch syndrome diagnostic testing pathways in endometrial cancers: a nationwide English registry-based study","","Background For female patients with Lynch syndrome, endometrial cancer is often the first cancer diagnosis. A somatic tumour testing triage followed by germline mismatch repair gene testing is an effective strategy to identify the estimated proportion of endometrial cancers caused by Lynch syndrome. Methods Retrospective national population-based analysis used English National Cancer Registration Dataset results for functional, somatic and germline MMR tests in 2019. Results Tumour testing, MLH1 promoter hypermethylation and germline testing proportions varied by Cancer Alliance and age, with substantial delays and attrition. Conclusion Regional variation and missed opportunities informed baseline evaluation for universal reflex testing guidance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lynch-syndrome-diagnostic-testing-pathways-in-endometrial-cancers-a-nationwide-english-registry-based-study/338592/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lynch-syndrome-diagnostic-testing-pathways-in-endometrial-cancers-a-nationwide-english-registry-based-study/338592.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What testing pathway is evaluated for Lynch syndrome in endometrial cancers?","Question",{"text":113,"@type":114},"The study evaluates a pathway starting with somatic tumour testing triage, followed by germline mismatch repair gene testing.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients and testing results identified in the national study?",{"text":118,"@type":114},"The analysis used comprehensive national data collections within the English National Cancer Registration Dataset, focusing on endometrial cancer diagnoses in 2019 with available functional, somatic and germline MMR tests.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key findings about testing proportions and delays?",{"text":122,"@type":114},"Tumour testing and downstream MLH1 promoter hypermethylation and germline testing proportions varied by Cancer Alliance and age, and there were delays between cancer diagnosis and germline MMR testing, indicating attrition and missed opportunities to diagnose Lynch syndrome.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338592,1790180350,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Cancer genetics  \nOriginal research  \nLynch syndrome diagnostic testing pathways in endometrial cancers: a nationwide English registrybased study  \nLucy Loong, 1,2 Catherine Huntley, 1,2 Joanna Pethick,2 Fiona McRonald,2 Francesco Santaniello,2,3 Brian Shand,2 Oliver Tulloch,2 Shilpi Goel,2,3  \nMargreet Lüchtenborg,2,4 Sophie Allen  , 1,2 Bethany Torr  , 1 Katie Snape  ,5 Angela George,6,7 Fiona Lalloo,8 Gail Norbury,9 Diana M Eccles  , 10  \nMarc Tischkowitz, 11 Antonis C Antoniou  , 12 Paul Pharoah, 13 Adam Shaw  , 14 Eva Morris, 15 John Burn, 16 Kevin Monahan, 17,18 Steven Hardy,2 Clare Turnbull  1,2  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1136/jmg-2024-110231](10.1136/jmg-2024-110231)) .  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Clare Turnbull; [turnbull.lab@icr.ac.uk](turnbull.lab@icr.ac.uk)  \nLL and CH contributed equally.  \nReceived 11 July 2024  \nAccepted 18 September 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.  \nTo cite: Loong L, Huntley C, Pethick J, et al. J Med Genet Epub ahead of print: [please include Day Month Year] . doi:10 . 1136/jmg-2024- 110231  \nABSTRACT  \nBackground For female patients with Lynch syndrome (LS), endometrial cancer (EC) is often their first cancer diagnosis. A testing pathway of somatic tumour testing triage followed by germline mismatch repair (MMR) gene testing is an effective way of identifying the estimated 3% of EC caused by LS.  \nMethods A retrospective national population-based observational study was conducted using comprehensive national data collections of functional, somatic and germline MMR tests available via the English National Cancer Registration Dataset. For all EC diagnosed in 2019, the proportion tested, median time to test, yield of abnormal results and factors influencing testing pathway initiation were examined.  \nResults There was an immunohistochemistry (IHC) or microsatellite instability (MSI) test recorded for 17.8%(1408/7928) of patients diagnosed with EC in 2019. Proportions tested varied by Cancer Alliance and age. There was an MLH1 promoter hypermethylation test recorded for 43 . 1%(149/346) of patients with MLH1 protein IHC loss or MSI. Of patients with EC eligible from tumour-testing, 25%(26/104) had a germline MMR test recorded. Median time from cancer diagnosis to germline MMR test was 315 days (IQR 222–486) .  \nConclusion This analysis highlights the regional variation in recorded testing, patient attrition, delaysand missed opportunities to diagnose LS, providing an informative baseline for measuring the impact of the national guidance from the National Institute for Health and Care Excellence on universal reflex LS testing in EC, implemented in 2020.  \nINTRODUCTION  \nLynch syndrome (LS) is characterised by an elevated genetic risk of gastrointestinal and gynaecological cancers, in particular colorectal cancer (CRC) and endometrial cancer (EC). LS is caused by germline inactivation of one of four genes acting in DNA mismatch repair (dMMR) pathways (MLH1, MSH2, MSH6 and PMS2), typically due to inherited pathogenic variants (PVs).1 2 Early identification of patients with LS offers opportunities to  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Existing evidence describes how universal reflex mismatch repair tumour testing, compared with post hoc order-initiated testing, leads to increased proportions of patients with endometrial cancer receiving testing for Lynch syndrome.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study is the first national evaluation of the diagnostic testing pathway for Lynch syndrome in patients with endometrial cancer, and the first to examine delays between diagnosis and test receipt.\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ This study highlights regional variation, delaysand missed opportunities to di","cbCainaZXbi8StYD","https://ap.wps.com/l/cbCainaZXbi8StYD","pdf",1257087,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## What is already known on this topic\n## What this study adds\n## How this study might affect research, practice or policy","[{\"question\":\"What testing pathway is evaluated for Lynch syndrome in endometrial cancers?\",\"answer\":\"The study evaluates a pathway starting with somatic tumour testing triage, followed by germline mismatch repair gene testing.\"},{\"question\":\"How were patients and testing results identified in the national study?\",\"answer\":\"The analysis used comprehensive national data collections within the English National Cancer Registration Dataset, focusing on endometrial cancer diagnoses in 2019 with available functional, somatic and germline MMR tests.\"},{\"question\":\"What were the key findings about testing proportions and delays?\",\"answer\":\"Tumour testing and downstream MLH1 promoter hypermethylation and germline testing proportions varied by Cancer Alliance and age, and there were delays between cancer diagnosis and germline MMR testing, indicating attrition and missed opportunities to diagnose Lynch syndrome.\"}]","Lynch syndrome diagnostic testing pathways in endometrial cancers: a nationwide English registry-based study | PDF",1790024380,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e5b3d2bfaf40bec7db25189d27014d8.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a78e98baed45fd8acca33e93ad1424d7.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2edfb2c9fd7a6950cf20105b2f7f03b.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a6753c91870cec084277e7bebb3e2ec.webp",980,1306]